Bioequivalence study of Mirabegron 50 mg extended-release tablets

Bioequivalence study of Mirabegron 50 mg slow-release tablets from Teb Mofid Nikan Pharmaceutical Company compared to Mirabegron 50 mg slow-release tablets from Astellas, UK, on ??healthy volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230222057495N32

Enrollment

Registered

2025-11-11

Start date

2025-11-01

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention 1: Intervention group 1: Includes oral administration of Mirabegron 50 mg slow-release tablets from Teb Mofid Nikan Pharmaceutical Company, Iran, on 24 healthy fasting volunteers. 5 ml of

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Healthy volunteers between the ages of 18 and 55. Body mass index less than 30 kg/m2. All volunteers must be non-smokers.

Exclusion criteria

Exclusion criteria: Blood pressure less than 90 on 60 mm Hg or more than 140 on 90 mm Hg. Consumption of any drug, alcohol or tobacco within 2 weeks before receiving the drug

Design outcomes

Primary

Measure	Time frame
Maximum plasma concentration of mirabegron. Timepoint: Before starting the drug and: 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 8,10, 24, 48 and 72 hours after taking the drug. Method of measurement: Liquid chromatography - mass spectrometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMonireh Jalalipour

Nik Azma Pars Alborz Laboratory

info@naplab.ir+98 26 3731 5789

Outcome results